StockNews.AI
IMRX
StockNews.AI
64 days

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

1. Immuneering announces a conference call for June 17, 2025. 2. Updates on Phase 2a clinical trial for IMM-1-104 in pancreatic cancer. 3. IMM-1-104 targets MAPK pathway-driven tumors, enhancing treatment options. 4. Company's focus is on improving treatment durability and tolerability. 5. Investor relations accessible via the company's website.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming conference call can attract investor interest and optimism about clinical trials, similar to past successes in biotech stocks after similar announcements.

How important is it?

The announcement's focus on clinical trials and their significance for oncology aligns closely with IMRX's core business model.

Why Short Term?

The immediate market response to the conference call may influence short-term stock price movements.

Related Companies

VRTXADXSCLDX
CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The conference call will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation. About Immuneering Corporation Immuneering is a clinical-stage oncology company outpacing cancer to help patients outlive their disease. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com. Media Contact: Jenna Urban jurban@cglife.com Investor Contact: Laurence Watts 619-916-7620 laurence@newstreetir.com

Related News